Frank Torti
CIK 1647805 · President and Vant Chair · last filed 2026-11-12
Frank Torti is a President and Vant Chair who has filed 36 SEC Form 4 insider transactions across 8 companies since 2018. The most recent filing, for ROIV, was dated Nov 12, 2026. Across all open-market trades the lifetime net is −$81.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $514.9M across reported positions. 10 SEC filings were submitted jointly with Roivant Sciences Ltd. 4 Form 144 notices of planned sales are also on file; the latest, for ROIV on Nov 10, 2026, lists the filer as an officer.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ROIV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 205
ASPEN, CO 81611
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ROIV | President and Vant Chair | 12,306,950 | $39.17 | $482.12M | -$82.04M | 7 | 2026-11-12 |
| IMVT | Director | 1,009,228 | $32.51 | $32.81M | $116.2K | 8 | 2026-04-09 |
| ABUS | Director | — | $4.08 | — | $0 | 7 | 2024-05-24 |
| Sio Gene Therapies Inc. (SIOX) Delisted | Director | — | $0.48 | — | $0 | 1 | 2021-04-19 |
| Immunovant, Inc. (IMVTW) Delisted | Director | 28,400 | — | — | $0 | 2 | 2020-05-18 |
| Sio Gene Therapies Inc. (AXGT) Delisted | Director | — | — | — | $0 | 1 | 2020-04-17 |
| Myovant Sciences Ltd. (MYOV) Delisted | Director | — | $26.98 | — | $0 | 2 | 2019-08-27 |
| Urovant Sciences Ltd. (UROV) Delisted | Director | — | $16.24 | — | $0 | 2 | 2019-07-11 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-11-12 | ROIV | Mixed | −1,188,943 | -$48.79M | EDGAR |
| 2026-11-10 | ROIV | Notice (144/A) Officer · Planned Nov 10, 2026 No sale on file yet |
−1,234,964 | -$50.73M | EDGAR |
| 2026-10-02 | ROIV | Tax (F) | +40,309 | $1.47M | EDGAR |
| 2026-07-02 | ROIV | Tax (F) | −40,310 | -$1.43M | EDGAR |
| 2026-04-09 | IMVT | Grant (A) | +174,189 | $0 | EDGAR |
| 2026-04-02 | ROIV | Tax (F) | −160,035 | -$4.43M | EDGAR |
| 2026-02-23 | ROIV | Mixed10b5-1 | — | -$70.49M | EDGAR |
| 2026-02-20 | ROIV | Notice (144) Officer · Planned Feb 20, 2026 · 10b5-1 plan Sold: Form 4 filed Feb 23, 2026 |
−1,600,000 | -$44.03M | EDGAR |
| 2026-02-19 | ROIV | Notice (144) Officer · Planned Feb 19, 2026 · 10b5-1 plan Sold: Form 4 filed Feb 23, 2026 |
−1,400,000 | -$38.47M | EDGAR |
| 2025-12-29 | ROIV | Notice (144) Officer, Director · Planned Dec 24, 2025 Sold: listed on the Feb 20, 2026 notice |
−64,891 | -$1.46M | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).